🧫 Experiment Protocol
Validationproposed
SUMMARY
# FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutation Carriers Develop FXTAS
## Background and Rationale
This experiment addresses a fundamental question in neurogenetics: why only approximately 40% of individuals carrying FMR1 premutation alleles (55-200 CGG repeats) develop Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS), while the remainder remain asymptomatic throughout life. This incomplete penetrance represents a critical knowledge gap with profound implications for genetic c
METHODOLOGY NOTES
**Phase 1: Cohort Recruitment and Characterization (Months 1-6)**
• Recruit 500 FMR1 premutation carriers (55-200 CGG repeats) aged 50-85 years through genetics clinics and fragile X family registries
• Stratify into affected (n=200, clinically diagnosed FXTAS) and unaffected (n=300, asymptomatic carriers)
• Obtain detailed medical histories, family pedigrees, and environmental exposure questionnaires
• Collect blood samples for DNA/RNA extraction and establish lymphoblastoid cell lines
• Perform comprehensive neurological examinations using standardized FXTAS rating scales
**Phase 2: Genetic and Molecular Analysis (Months 4-12)**
• Quantify FMR1 CGG repeat lengths using Southern blot and PCR-based methods
• Measure FMR1 mRNA levels in blood using qRT-PCR (normalize to GAPDH)
• Assess FMRP protein levels via Western blot and immunofluorescence
• Conduct genome-wide SNP analysis to identify modifier loci using Illumina arrays
• Analyze epigenetic modifications including DNA methylation